Compare Pfizer Inc (PFE) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Pfizer Inc trades at $28.2 (market cap $158.56B), while ProShares UltraPro Short QQQ ETF trades at $32.95 (market cap $2.23B). The key difference: Pfizer Inc is far larger — about 71.1× ProShares UltraPro Short QQQ ETF's market cap, and Pfizer Inc pays a 6.18% dividend while ProShares UltraPro Short QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and ProShares UltraPro Short QQQ ETF for 12 Days on average.
| PFE | SQQQ | |
|---|---|---|
Market Cap | $158.56B | $2.23B |
Volume | 44,138,282 | 60,436,012 |
Sector | Health | Leveraged / Inverse |
52-Week High | $29.02 | $89.43 |
52-Week Low | $23.67 | $31.83 |
Typical Hold Time | 158 Days | 12 Days |
Enterprise Value | $210.06B | — |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
SQQQ, the ProShares UltraPro Short QQQ ETF, is currently trading at $33.02, up 2.93% on the day. The technical picture remains bearish with moving averages signaling continued downward pressure, though oscillators show neutral momentum. As a 3x leveraged inverse ETF designed to profit from Nasdaq 100 declines, SQQQ's performance is directly tied to technology sector weakness. Recent news highlights its potential role as a hedging tool against QQQ holdings during market downturns.
The outlook for SQQQ depends heavily on technology sector performance, with potential gains during Nasdaq 100 declines but significant decay risk during sustained rallies. Investors face substantial volatility risks due to daily rebalancing and compounding effects. Current market conditions suggest continued uncertainty for tech stocks, potentially supporting SQQQ's short-term appeal as a tactical hedge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
